Exclusion criteria for analysis. BTKi, Bruton tyrosine kinase inhibitor; HAART, highly active antiretroviral therapy; LTFU, lost to follow up; R-MVP, rituximab, methotrexate, procarbazine, vincristine; R-VIA, rituximab, etoposide, ifosfamide, cytarabine; TEDDI-R, temozolomide, etoposide, doxil, dexamethasone, ibrutinib, rituximab; TR, temozolomide rituximab.